Skip to main content
Clinical Trials/NCT03986580
NCT03986580
Active, not recruiting
Not Applicable

Prospective Evaluation Of Lumbar Discectomy With Additional Implantation Of An Annular Closure Device In Patients With Large Postsurgical Annular Defects For Prevention Of Lumbar Disc Reherniation

Intrinsic Therapeutics7 sites in 1 country55 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lumbar Disc Herniation
Sponsor
Intrinsic Therapeutics
Enrollment
55
Locations
7
Primary Endpoint
Hospital readmission occurrence
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this prospective, single-arm, multicenter study is to assess an annular closure device when used as an adjunct to a primary lumbar limited discectomy, to limited discectomy alone.

Detailed Description

This single-arm case series will enroll 75 patients at select US (approximately 8-10) sites. Patients that are scheduled for a single-level L4-S1 discectomy and who meet the pre-operative eligibility criteria will be considered for study participation. Patients that meet all intraoperative criteria will be enrolled into the study and treated with lumbar discectomy and additional annular closure device implantation. All enrolled subjects will be followed for at least 12 months.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
December 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Intrinsic Therapeutics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 to 75 years old and skeletally mature (male or female)
  • Subjects with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. \[Note: Intraoperatively, only patients with an anular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.\]
  • At least six (6) weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections.;
  • Minimum posterior disc height of 5mm at the index level.
  • Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees)
  • Oswestry Questionnaire score of at least 40/100 at baseline.
  • VAS leg pain (one or both legs) of at least 40/100 at baseline.
  • Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.

Exclusion Criteria

  • Spondylolisthesis Grade II or higher (25% slip or greater).
  • Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed).
  • Subject has back or non-radicular leg pain of unknown etiology.
  • Prior surgery at the index lumbar vertebral level
  • Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.
  • Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
  • Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip
  • Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).
  • Any metabolic bone disease.
  • Subject has an active infection either systemic or local.

Outcomes

Primary Outcomes

Hospital readmission occurrence

Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year

Change from baseline in incidence of re-admissions to hospital, post treatment

Procedure time

Time Frame: Intra-operative

Length of surgery, measured in minutes

ODI

Time Frame: Baseline, 4 Weeks, 3 Months, 1 year

Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability

Neurological assessment

Time Frame: Baseline, 4 Weeks, 3 Months, 1 year

Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as "normal", "increased", "absent" and "decreased") and muscle strength measured 0-5 with "0" representing no evidence of motor strength and "5" representing full resistance

Leg pain severity (0-100 VAS score)

Time Frame: Baseline, 4 Weeks, 3 Months, 1 year

Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome

Satisfaction with surgery procedure

Time Frame: 1 year

Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others

Adverse events

Time Frame: Baseline, Intra-operative, 4 Weeks, 3 Months, 1 year

Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure

Blood loss

Time Frame: Intra-operative

Amount of blood loss measured in ml

Hospital stay

Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)

Length of the hospital stay measured in days between hospital admission and hospital discharge

Back pain severity (0-100 VAS score)

Time Frame: Baseline, 4 Weeks, 3 Months, 1 year

Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome

EQ-5D

Time Frame: Baseline, 4 Weeks, 3 Months, 1 year

Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension

Reoperation incidence

Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year

Change from baseline in incidence of post-operative reoperation at the index level

Return to work assessment

Time Frame: 4 Weeks, 3 Months, 1 year

Change from baseline in work status (ability to return to work, with or without reported restrictions)

Discharge status

Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)

Evaluation of improvement in motor and sensory neurologic status

Symptomatic reherniation incidence

Time Frame: Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year

Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review

Opioid consumption

Time Frame: Baseline, Intra-operative, Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year

Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)).

Study Sites (7)

Loading locations...

Similar Trials